Empirically defining trajectories of late-life cognitive and functional decline

Manuscript Number: 

15-0563R1

Author(s): 
MIchael Case, Elisabeth Degenhardt, David B. Henley, Helen Hochstetler, Jeannie-Marie Leoutsakos, Constantine G. Lyketsos, Paula T. Trzepacz, Shufang Wang, Peng Yu

Disclosures

MIchael Case

  • Equity:
    Minor shareholder in Eli Lilly and Company
    Sponsors:
    Project statistician for Eli Lilly and Company

Elisabeth Degenhardt

  • Nothing to Disclose

David B. Henley

  • Equity:
    minor shareholder and employee Eli Lilly and Co.
    Sponsors:
    employee of Eli Lilly and Co.

Helen Hochstetler

  • Equity:
    Eli Lilly company stock
    Sponsors:
    Clinical Research Scientist for Eli Lilly

Jeannie-Marie Leoutsakos

  • Nothing to Disclose

Constantine G. Lyketsos

  • Consulting Fees:
    AstraZeneca, GlaxoSmithKline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, NFL Players Association, NFL Benefits Office, Avanir, Zinfandel, BMS, Abvie, Janssen, Orion, Otsuka, Servier, Astellas
    Lecture Fees:
    Honorarium or travel support from Pfizer, Forest, GlaxoSmithKline, Health Monitor
    Grants
    • Agency: 
      Forest, GlaxoSmithKline, Eisai, Pfizer, AstraZeneca, Lilly, Ortho-McNeil, Bristol-Myers, Novartis, National Football League, Elan, Functional Neuromodulation
      Dates: 
      Various

Paula T. Trzepacz

Shufang Wang

  • Sponsors:
    I am a statistician in Eli Lilly and Company.

Peng Yu

  • Equity:
    small stock holder of Eli Lilly and Company